Reduction in human immunodeficiency virus type 1 mutations associated with drug resistance after initiating new therapeutic regimens in pretreated patients
ANTI-HIV AGENTS;
DRUG RESISTANCE, MICROBIAL;
DRUG RESISTANCE, MULTIPLE;
DRUG THERAPY, COMBINATION;
HIV INFECTIONS;
HIV-1;
HUMANS;
MUTATION;
POLYMERASE CHAIN REACTION;
SALVAGE THERAPY;
TIME FACTORS;
A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy
Alexandria, VA: Foundation for Retrovirology and Human Health
2. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Merigan TC. the CPCRA 046 Study Team. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. In: Proceedings and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999:LB8.
Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
3. Devereux HL, Youle M, Johnson M, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999;13: F123-7.
Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment
4. Winters MA, Schapiro JM, Lawrence J, Merigan TC. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. J Virol 1998;72:5303-6.
Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors
5. Dulioust A, Paulous S, Guillemot L, Delavalle AM, Boue F, Clavel F. Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors. J Virol 1999;73: 850-4.
Surrogate marker responses to multidrug combinations comprising hydroxyurea, efavirenz, double protease inhibitors and nucleoside analogues in protease inhibitor failures
Alexandria, VA: Foundation for Retrovirology and Human Health
6. Youle M, Mocroft A, Johnson M, et al. Surrogate marker responses to multidrug combinations comprising hydroxyurea, efavirenz, double protease inhibitors and nucleoside analogues in protease inhibitor failures. In: Proceedings and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999:400.
